EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK

Translational Oncology

Volumn 5, Issue 5, 2012, Pages 327-334

  Mueller, Kelly L ^a   Powell, Katelyn ^a   Madden, Julie M ^a   Eblen, Scott T ^b   Boerner, Julie L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; TYROSINE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PROTEIN PHOSPHORYLATION;

EID: 84867567373     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12163     Document Type: Article

References (28)

1. Wheeler DL, Dunn EF, and Harari PM (2010). Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7, 493-507.
2. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M, and Milano G (2001). Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12, 841-846.
3. Klijn JG, Berns PM, Schmitz PI, and Foekens JA (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13, 3-17.
4. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, and Oda S (2002). Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71, 67-75.
5. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, et al. (2005). Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23, 5323-5333.
6. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, et al. (2004). Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22, 3080-3090.
7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
8. Kopetz S, Shah AN, and Gallick GE (2007). Src continues aging: current and future clinical directions. Clin Cancer Res 13, 7232-7236.
9. Mueller KL, Hunter LA, Ethier SP, and Boerner JL (2008). Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 68, 3314-3322.
10. Mueller KL, Yang ZQ, Haddad R, Ethier SP, and Boerner JL (2010). EGFR/ Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 5, 8.
11. Dimri M, Naramura M, Duan L, Chen J, Ortega-Cava C, Chen G, Goswami R, Fernandes N, Gao Q, Dimri GP, et al. (2007). Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res 67, 4164-4172.
12. Maa MC, Leu TH, McCarley DJ, Schatzman RC, and Parsons SJ (1995). Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92, 6981-6985.
13. Tice DA, Biscardi JS, Nickles AL, and Parsons SJ (1999). Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96, 1415-1420.
14. Biscardi JS, Ishizawar RC, Silva CM, and Parsons SJ (2000). Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2, 203-210.
15. Boerner JL, Biscardi JS, Silva CM, and Parsons SJ (2005). Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 44, 262-273.
16. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, and Davis RJ (1998). A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281, 1671-1674.
17. Vomastek T, Iwanicki MP, Burack WR, Tiwari D, Kumar D, Parsons JT, Weber MJ, and Nandicoori VK (2008). Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol 28, 6954-6966.
18. Xu YH, Richert N, Ito S, Merlino GT, and Pastan I (1984). Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci USA 81, 7308-7312.
19. Willmarth NE and Ethier SP (2006). Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem281, 37728-37737.
20. Irwin ME, Mueller KL, Bohin N, Ge Y, and Boerner JL (2010). Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 226, 2316-2328.
21. Kallin A, Demoulin J-B, Nishida K, Hirano T, Rönnstrand L, and Heldin C-H (2004). Gab1 contributes to cytoskeletal reorganization and chemotaxis in response to platelet-derived growth factor. J Biol Chem 279, 17897-17904.
22. Mattoon D, Lamothe B, Lax I, and Schlessinger J (2004). The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol 2, 24.
23. Bradham C and McClay DR (2006). p38 MAPK in development and cancer. Cell Cycle 5, 824-828.
24. Olson JM and Hallahan AR (2004). p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10, 125-129.
25. Thornton TM and Rincon M (2009). Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 5, 44-51.
26. Wagner EF and Nebreda AR (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549.
27. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, and Bacus SS (2004). Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100, 499-506.
28. Mikami F, Gu H, Jono H, Andalibi A, Kai H, and Li JD (2005). Epidermal growth factor receptor acts as a negative regulator for bacterium nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via an Srcdependent p38 mitogen-activated protein kinase signaling pathway. J Biol Chem 280, 36185-36194.